OS6.4 NOA-16: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group evaluating a mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas
Michael Platten(German Cancer Research Center), Wolfgang Wick(German Cancer Research Center), J Hense, A Weyerbrock(University of Freiburg), D Krex, Lukas Bunse(German Cancer Research Center), Irini Karapanagiotou‐Schenkel(German Cancer Research Center), J Steinbach(Goethe University Frankfurt), Dennis Riehl(Johannes Gutenberg University Mainz), S Setvanovic(University of Tübingen), Antje Wick(Heidelberg University), E Green(Heidelberg University), Khwab Sanghvi(Heidelberg University), Martin Misch(Humboldt-Universität zu Berlin), Andreas von Deimling(German Cancer Research Center), Inga Harting(Heidelberg University), Felix Sahm(German Cancer Research Center), Ghazaleh Tabatabai(Goethe University Frankfurt), Theresa Bunse(German Cancer Research Center), M. Schmitt(Heidelberg University), Daniela Schilling(National Center for Tumor Diseases)
Cited by 3
Related Papers
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
|The Lancet Oncology|2017|1.1k